Drug Trial Radar · NCT00887536
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,613
Actual
Start
May 2009
Primary completion
Feb 2018
Study completion Feb 2018
Sponsor
- Lead sponsor
- NSABP Foundation IncResearch network
- Sponsor type
- Research network
- Collaborators
- Genentech, Inc.; US Oncology Research
- First posted
- Apr 24, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.
Conditions
- Breast Cancer
Interventions
bevacizumabDrug
bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
docetaxelDrug
docetaxel 75 mg/m2 IV every 21 days for 6 cycles
doxorubicinDrug
doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
cyclophosphamideDrug
Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles
pegfilgrastimDrug
pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival(IDFS)relative to the TAC chemotherapy regimen aloneTime frame: Every 12 months until recurrence
Locations
533 sites in 2 countries. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology
Bessemer, Alabama
Birmingham Hematology and Oncology
Birmingham, Alabama
Birmingham Hematology and Oncology - Brookwood
Birmingham, Alabama
Birmingham Hematology and Oncology - Princeton
Birmingham, Alabama
Birmingham Hematology and Oncology - Montclair
Birmingham, Alabama
Birmingham Hematology and Oncology - Pilot
Birmingham, Alabama
Clearview Cancer Institute- Huntsville
Huntsville, Alabama
Northern Arizona Hematology & Onclogy Associates
Flagstaff, Arizona
Arizona Oncolocy (CASA-Green Valley)
Green Valley, Arizona
Arizona Oncology (CASA- Oro Valley)
Oro Valley, Arizona
Hematology Oncology Associates
Phoenix, Arizona
Northern Arizona Hematology & Oncology Associates
Prescott Valley, Arizona
Arizona Oncology (CASA-Safford)
Safford, Arizona
Hematology Oncology Associates
Scottsdale, Arizona
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona
Arizona Oncology Associates - Rudasill
Tucson, Arizona
Arizona Oncology Associates - Carondelet
Tucson, Arizona
Arizona Oncology (CASA-Craycroft)
Tucson, Arizona
Arizona Oncology (CASA-Office Only)
Tucson, Arizona
Arizona Oncology - CASA St. Mary's
Tucson, Arizona
Central Hematology/Oncology Medical Group, Inc.
Alhambra, California
Kaiser Permanente Deer Valley Med Center
Antioch, California
Comp Blook and Cancer Center
Bakersfield, California
Southwest Cancer Care (E. Grand)
Escondido, California
Kaiser Permanente Fremont
Fremont, California
St. Jude Heritage Healthcare
Fullerton, California
Kaiser Permanente Medical Center - Hayward
Hayward, California
Pacific Shores Medical Group
Huntington Beach, California
Southern California Permanente Medical Group
Irvine, California
Wilshire Oncology Medical Group (Business Office)
La Verne, California
Antelope Valley Cancer Center
Lancaster, California
Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center
Long Beach, California
Todd Cancer Institute at Long Beach Memorial Med Cent
Long Beach, California
Pacific Shores Medical Group
Long Beach, California
Pacific Shores Medical Group
Los Alamitos, California
TORI- N Valley Hematology Oncology Med Group
Mission Hills, California
TORI - Oncology Care Medical Assoc.
Montebello, California
Southwest Cancer Care (Medical Center)
Murrieta, California
NValley Hematology/Oncology Medical Group
Northridge, California
Kaiser Permanente-Oakland
Oakland, California
Showing 40 of 533 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.